Table 2. Evolution of plasma tHcy and betaine in patients with acquired HHcy after treatment with B12 vitamin.
| Patient number | Pathology | Treatment ↓ | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 | B12 deficiency | Time after treatment (days) | 0 | 6 | 9 | 13 | |||||||||
| tHcy (μM) | 124 | 6 | 5 | 5 | |||||||||||
| Betaine (μM) | 8 | 38 | 25 | 28 | |||||||||||
| 10 | B12 deficiency | Time after treatment (days) | 0 | 4 | 6 | 10 | |||||||||
| tHcy (μM) | 90 | 10 | 3 | 3 | |||||||||||
| Betaine (μM) | 12 | 17 | 15 | 49 | |||||||||||
| 11 | B12 deficiency | Time after treatment (days) | 0 | 5 | 16 | ||||||||||
| tHcy (μM) | 122 | 8 | 6 | ||||||||||||
| Betaine (μM) | 7 | 8 | 30 | ||||||||||||
| 12 | B12 deficiency | Time after treatment (days) | 0 | 6 | 60 | ||||||||||
| tHcy (μM) | 125 | 6 | 6 | ||||||||||||
| Betaine (μM) | 10 | 30 | 28 | ||||||||||||
| 13 | B12 deficiency | Time after treatment (days) | 0 | 5 | |||||||||||
| tHcy (μM) | 111 | 67 | |||||||||||||
| Betaine (μM) | 13 | 14 | |||||||||||||
| 14 | N2O-induced HHcy | Time after treatment (days) | 0 | 24 | 68 | 80 | |||||||||
| tHcy (μM) | 155 | 66 | 23 | 6 | |||||||||||
| Betaine (μM) | 11 | 75 | 57 | 82 | |||||||||||
| 15 | Folate deficiency | Time after treatment (days) | 0 | ND | |||||||||||
| tHcy (μM) | 59 | ||||||||||||||
| Betaine (μM) | 14 | ||||||||||||||
| 16 | Methotrexatetreatment | Time after treatment (days) | 0 | ND | |||||||||||
| tHcy (μM) | 40 | ||||||||||||||
| Betaine (μM) | 12 | ||||||||||||||
| 17 | Methotrexate treatment | Time after treatment (days) | 0 | ND | |||||||||||
| tHcy (μM) | 31 | ||||||||||||||
| Betaine (μM) | 15 | ||||||||||||||
N2O, nitrous oxide
ND, no data